IPNP2015 is a proprietary triple reuptake inhibitor of 5-HT, NA, and DA. Initiator has tested IPNP2015 in rodent models of persistent and neuropathic pain. IPNP2015 possesses superior antinociceptive efficacy compared with the dual monoamine reuptake inhibitor duloxetine, and it is an attractive new drug candidate for the treatment of chronic pain. In preclinical studies, IPNP2015 has shown positive effects in comparison with the drug duloxetine.
Neuropathic pain is a devastating condition that affects millions of patients globally. The market for the symptom was estimated at approximately USD 6.3 billion in 2019 and is expected to increase to approximately USD 10 billion by 2027. It is a multifactorial disease where recommended first-line treatments include selected antidepressants (i.e., tricyclic antidepressants and dual serotonin and norepinephrine reuptake inhibitors), calcium channel alpha2-delta ligands (i.e., gabapentin and pregabalin), and lidocaine. Opioid analgesics and tramadol are generally recommended as the second line treatment, considered for first-line use in specific clinical circumstances. Despite the availability of several different treatment options, less than 50 percent of patients experience meaningful pain relief. With the lack of effective treatments, these areas have a large unsatisfied need, creating opportunities to develop new therapies.
 Coherent Market Insights “Neuropathic Pain Market Analysis” (2020), https://www.coherentmarketinsights.com/market-insight/neuropathic-pain-market-3656.
 Finnerup, Nanna B., et al. “Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.” The Lancet Neurology 14.2 (2015): 162-173.
*Both IPDP2015 and IPNP2015 have been included in a screening agreement with the US National Institute on Drug Abuse to evaluate their anti-addictive properties. Specifically, NIDA’s Addiction Treatment Discovery Program will work closely with the company to determine the effects of IPDP2015 and IPPD2015 on cocaine- and methamphetamine-related behaviors using established preclinical rodent models through its contract resources.